- Home
- CANF vs BTX Comparison
CANF vs BTX Comparison
Compare CANF & BTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CANF | BTX |
|---|---|---|
| Founded | 1994 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 780.8M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | CANF | BTX |
|---|---|---|
| Price | $3.72 | $6.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9,750.00 | N/A |
| AVG Volume (30 Days) | 631.0K | ★ 704.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.82% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $461.72 | N/A |
| Revenue Next Year | $290,391.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $5.10 |
| 52 Week High | $10.40 | $7.50 |
Technical Indicators
Market Signals| Indicator | CANF | BTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 43.48 |
| Support Level | $0.60 | $6.23 |
| Resistance Level | $4.74 | $6.94 |
| Average True Range (ATR) | 0.71 | 0.17 |
| MACD | -0.17 | -0.01 |
| Stochastic Oscillator | 0.40 | 25.42 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
About BTX BlackRock Technology and Private Equity Term Trust
BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.